In a Japanese study, approximately 1 in 8 CKD patients with anemia failed to respond to darbepoetin alfa therapy. Specific factors may predict better initial response to darbepoetin alfa in patients ...
Only about a quarter of patients who have myelodysplastic syndrome (MDS) experienced hematologic improvement with erythropoiesis-stimulating agents (ESAs). Patients with lower-risk myelodysplastic ...
Quarter of Metastatic PCa Patients Had Synchronous Cancer A recent study resulted in a new definition of less-than-optimal response to erythropoiesis-stimulating agents. Investigators have identified ...
Experts offered pointers on appropriate use of iron therapies, erythropoiesis stimulating agents (ESAs), and hypoxia inducible factor inhibitors (HIF-PHI) for anemia of chronic kidney disease (CKD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results